| Literature DB >> 15506675 |
Urs Eiholzer1, Barbara Y Whitman.
Abstract
Prader-Willi syndrome (PWS) is a genetic disorder characterized by extreme obesity accompanied by other, multisystem clinical manifestations encompassing both physical and behavioral/cognitive abnormalities. The multi-dimensional problems of patients with PWS cannot be treated with a single intervention and benefit from a team approach to management to optimize outcomes. Childhood stature below target height and reduced final height are some defining characteristics of PWS, and compelling evidence from growth hormone (GH) treatment trials suggests that hypothalamic GH deficiency exists. Treatment with GH has been shown to increase height velocity in children with PWS, decrease weight-for-height index values and body fat mass, and have a positive effect on lean body mass during at least the first year of therapy. In addition to medical concerns, the behavioral manifestations, including an uncorrectable deficit in appetite control, and cognitive limitations associated with PWS, require long-term multidisciplinary management.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15506675 DOI: 10.1515/jpem.2004.17.9.1153
Source DB: PubMed Journal: J Pediatr Endocrinol Metab ISSN: 0334-018X Impact factor: 1.634